Unraveling the Significance of EPH/Ephrin Signaling in Liver Cancer: Insights into Tumor Progression and Therapeutic Implications

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2023 Jul 14

PMID 37444544

Authors

Stavros P Papadakos

Ioanna E Stergiou

Nikolina Gkolemi

Konstantinos Arvanitakis

Stamatios Theocharis

Affiliations

Soon will be listed here.

Abstract

Liver cancer is a complex and challenging disease with limited treatment options and dismal prognosis. Understanding the underlying molecular mechanisms driving liver cancer progression and metastasis is crucial for developing effective therapeutic strategies. The EPH/ephrin system, which comprises a family of cell surface receptors and their corresponding ligands, has been implicated in the pathogenesis of HCC. This review paper aims to provide an overview of the current understanding of the role of the EPH/ephrin system in HCC. Specifically, we discuss the dysregulation of EPH/ephrin signaling in HCC and its impact on various cellular processes, including cell proliferation, migration, and invasion. Overall, the EPH/ephrin signaling system emerges as a compelling and multifaceted player in liver cancer biology. Elucidating its precise mechanisms and understanding its implications in disease progression and therapeutic responses may pave the way for novel targeted therapies and personalized treatment approaches for liver cancer patients. Further research is warranted to unravel the full potential of the EPH/ephrin system in liver cancer and its clinical translation.

Citing Articles

Advances and current concepts on Eph receptors and ephrins in upper digestive tract cancers.

Lavareze L, Kimura T, Scarini J, de Lima-Souza R, Goncalves M, Sales de Sa R Front Oncol. 2025; 14:1520306.

PMID: 39839790 PMC: 11746119. DOI: 10.3389/fonc.2024.1520306.

Upregulation of Differentiates Intrahepatic Cholangiocarcinoma from Hepatocellular Carcinoma and Both Colorectal and Pancreatic Adenocarcinoma Liver Metastases.

Draskovic T, Rankovic B, Zidar N, Hauptman N Genes (Basel). 2025; 15(12.

PMID: 39766812 PMC: 11675665. DOI: 10.3390/genes15121545.

DNA methylation biomarker panels for differentiating various liver adenocarcinomas, including hepatocellular carcinoma, cholangiocarcinoma, colorectal liver metastases and pancreatic adenocarcinoma liver metastases.

Draskovic T, Rankovic B, Zidar N, Hauptman N Clin Epigenetics. 2024; 16(1):153.

PMID: 39497215 PMC: 11536859. DOI: 10.1186/s13148-024-01766-z.

The Clinical Relevance of the EPH/Ephrin Signaling Pathway in Pediatric Solid and Hematologic Malignancies.

Chatzikalil E, Stergiou I, Papadakos S, Konstantinidis I, Theocharis S Int J Mol Sci. 2024; 25(7).

PMID: 38612645 PMC: 11011407. DOI: 10.3390/ijms25073834.

Interplay of Extracellular Vesicles and TLR4 Signaling in Hepatocellular Carcinoma Pathophysiology and Therapeutics.

Papadakos S, Arvanitakis K, Stergiou I, Vallilas C, Sougioultzis S, Germanidis G Pharmaceutics. 2023; 15(10).

PMID: 37896221 PMC: 10610499. DOI: 10.3390/pharmaceutics15102460.

References

Wu L, Zhou J, Zhou W, Huang X, Chen Q, Wang W . Sorafenib blocks the activation of the HIF-2α/VEGFA/EphA2 pathway, and inhibits the rapid growth of residual liver cancer following high-intensity focused ultrasound therapy in vivo. Pathol Res Pract. 2021; 220:153270. DOI: 10.1016/j.prp.2020.153270. View

Nagaoki Y, Imamura M, Nishida Y, Daijo K, Teraoka Y, Honda F . The impact of interferon-free direct-acting antivirals on clinical outcome after curative treatment for hepatitis C virus-associated hepatocellular carcinoma: Comparison with interferon-based therapy. J Med Virol. 2018; 91(4):650-658. DOI: 10.1002/jmv.25352. View

Machairas N, Tsilimigras D, Pawlik T . State-of-the-art surgery for hepatocellular carcinoma. Langenbecks Arch Surg. 2021; 406(7):2151-2162. DOI: 10.1007/s00423-021-02298-3. View

Carotenuto M, Sacco A, Forgione L, Normanno N . Genomic alterations in cholangiocarcinoma: clinical significance and relevance to therapy. Explor Target Antitumor Ther. 2022; 3(2):200-223. PMC: 9400790. DOI: 10.37349/etat.2022.00079. View

Khansaard W, Techasen A, Namwat N, Yongvanit P, Khuntikeo N, Puapairoj A . Increased EphB2 expression predicts cholangiocarcinoma metastasis. Tumour Biol. 2014; 35(10):10031-41. DOI: 10.1007/s13277-014-2295-0. View

Ikai I, Arii S, Kojiro M, Ichida T, Makuuchi M, Matsuyama Y . Reevaluation of prognostic factors for survival after liver resection in patients with hepatocellular carcinoma in a Japanese nationwide survey. Cancer. 2004; 101(4):796-802. DOI: 10.1002/cncr.20426. View

Zhang S, Li J, He F, Wang X . Abnormal nuclear expression of Pygopus-2 in human primary hepatocellular carcinoma correlates with a poor prognosis. Histopathology. 2014; 67(2):176-84. DOI: 10.1111/his.12637. View

Gupta A, Kurzrock R, Adashek J . Evolution of the Targeted Therapy Landscape for Cholangiocarcinoma: Is Cholangiocarcinoma the 'NSCLC' of GI Oncology?. Cancers (Basel). 2023; 15(5). PMC: 10000383. DOI: 10.3390/cancers15051578. View

Papatheodoridi M, Su T, Hadziyannis E, Liao C, Orfanidou A, Yang H . Hepatocellular carcinoma after treatment cessation in non-cirrhotic HBeAg-negative chronic hepatitis B: A multicentre cohort study. Liver Int. 2021; 42(3):541-550. DOI: 10.1111/liv.15128. View

10.

Takayasu K, Arii S, Kudo M, Ichida T, Matsui O, Izumi N . Superselective transarterial chemoembolization for hepatocellular carcinoma. Validation of treatment algorithm proposed by Japanese guidelines. J Hepatol. 2011; 56(4):886-92. DOI: 10.1016/j.jhep.2011.10.021. View

11.

Saviano A, Habersetzer F, Lupberger J, Simo-Noumbissie P, Schuster C, Doffoel M . Safety and Antiviral Activity of EGFR Inhibition by Erlotinib in Chronic Hepatitis C Patients: A Phase Ib Randomized Controlled Trial. Clin Transl Gastroenterol. 2022; 13(6):e00492. PMC: 9236598. DOI: 10.14309/ctg.0000000000000492. View

12.

Yuan Y, Zhou C, Chen X, Tao C, Cheng H, Lu X . Suppression of tumor cell proliferation and migration by human umbilical cord mesenchymal stem cells: A possible role for apoptosis and Wnt signaling. Oncol Lett. 2018; 15(6):8536-8544. PMC: 5950566. DOI: 10.3892/ol.2018.8368. View

13.

Papadakos S, Dedes N, Gkolemi N, Machairas N, Theocharis S . The EPH/Ephrin System in Pancreatic Ductal Adenocarcinoma (PDAC): From Pathogenesis to Treatment. Int J Mol Sci. 2023; 24(3). PMC: 9917762. DOI: 10.3390/ijms24033015. View

14.

Papadakos S, Dedes N, Kouroumalis E, Theocharis S . The Role of the NLRP3 Inflammasome in HCC Carcinogenesis and Treatment: Harnessing Innate Immunity. Cancers (Basel). 2022; 14(13). PMC: 9264914. DOI: 10.3390/cancers14133150. View

15.

Rahim M, Yoon Y, Dimovasili C, Shao Z, Huang Q, Zhang E . Presenilin1 familial Alzheimer disease mutants inactivate EFNB1- and BDNF-dependent neuroprotection against excitotoxicity by affecting neuroprotective complexes of -methyl-d-aspartate receptor. Brain Commun. 2020; 2(2):fcaa100. PMC: 7520050. DOI: 10.1093/braincomms/fcaa100. View

16.

Tian J, Liu W, Zhang Z, Tang L, Li D, Tian Z . Influence of miR-520e-mediated MAPK signalling pathway on HBV replication and regulation of hepatocellular carcinoma cells via targeting EphA2. J Viral Hepat. 2018; 26(4):496-505. DOI: 10.1111/jvh.13048. View

17.

Song Y, Zhao X, Song K, Shang Z . Ephrin-A1 is up-regulated by hypoxia in cancer cells and promotes angiogenesis of HUVECs through a coordinated cross-talk with eNOS. PLoS One. 2013; 8(9):e74464. PMC: 3767678. DOI: 10.1371/journal.pone.0074464. View

18.

Psilopatis I, Souferi-Chronopoulou E, Vrettou K, Troungos C, Theocharis S . EPH/Ephrin-Targeting Treatment in Breast Cancer: A New Chapter in Breast Cancer Therapy. Int J Mol Sci. 2022; 23(23). PMC: 9740341. DOI: 10.3390/ijms232315275. View

19.

Machairas N, Tsilimigras D, Pawlik T . Current Landscape of Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma. Cancers (Basel). 2022; 14(8). PMC: 9025403. DOI: 10.3390/cancers14082018. View

20.

Huang Z, Tipparaju S, Kirpotin D, Pien C, Kornaga T, Noble C . Formulation optimization of an ephrin A2 targeted immunoliposome encapsulating reversibly modified taxane prodrugs. J Control Release. 2019; 310:47-57. DOI: 10.1016/j.jconrel.2019.08.006. View